Aardvark Therapeutics Reports $21.6M Q1 Net Loss, $91.2M Cash to Fund Operations into Mid-2027 Amid Trial Pauses
Summary
Aardvark Therapeutics reported a net loss of $21.6 million for the first quarter of 2026, with its cash, cash equivalents, and short-term investments decreasing to $91.2 million as of March 31, 2026, from $110.0 million at year-end. This cash position is projected to fund operations into mid-2027. This financial update provides critical context following the company's previously announced voluntary pause in its Phase 3 HERO trial for ARD-101 and Phase 2 trials for ARD-201 due to reversible cardiac observations, a situation also highlighted in its recent 10-K filing and the establishment of a $150 million At-The-Market offering program. The significant cash burn of $18.8 million in Q1 is material for a small clinical-stage biotech with its lead programs on hold, underscoring the financial pressure. Investors will be closely monitoring for the expected guidance in Q2 2026 regarding the path forward for these paused programs, as their resolution is paramount for the company's future.
At the time of this announcement, AARD was trading at $5.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $128.5M. The 52-week trading range was $3.35 to $17.94. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.